A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00331292 |
Recruitment Status :
Terminated
First Posted : May 29, 2006
Last Update Posted : October 16, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Asthma |
Study Type : | Observational |
Enrollment : | 30 participants |
Time Perspective: | Prospective |
Official Title: | A Study to Identify a Transcriptomic Profile Indicative of Cycle AMP Pathway Activation in the Lung |
Study Start Date : | August 2006 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Have a history of intermittant asthma.
- Have asthma symptoms less than once per week.
- Have no other significant disease.
- Do not take regular oral or inhaled steroids.
- Are a non-smoker for the past 12 months with a pack history of less than 5 years.
Exclusion criteria:
- Have a history of drug or alcohol abuse.
- Have poorly controlled asthma or a history of life-threatening asthma.
- Have a history of hypersensitivity to bronchodilators.
- Are unable to abstain from inhaled steroids from 14 days prior to the first study visit until completion of the study.
- Have received oral steroids within 3 months of study entry.
- Have been hospitalized for your asthma within 3 months of study entry.
- Have had treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331292
United States, Pennsylvania | |
GSK Investigational Site | |
Philadelphia, Pennsylvania, United States, 19104 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | Study Director, GSK |
ClinicalTrials.gov Identifier: | NCT00331292 |
Other Study ID Numbers: |
CRB100706 |
First Posted: | May 29, 2006 Key Record Dates |
Last Update Posted: | October 16, 2008 |
Last Verified: | October 2008 |
Asthma bronchoscopy |
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |